# NervGen Pharma Corp. (NGEN)

Source: https://www.quantisnow.com/company/NGEN
Generated: 2026-11-06T23:24:05.910Z

- Ticker: NGEN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001751912

## Latest NGEN news and filings

- 2026-10-16 20:31 UTC [SEC Form 6-K] [Amendment: SEC Form 6-K/A filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/amendment-sec-form-6-ka-filed-by-nervgen-pharma-corp-6749306)
- 2026-10-16 20:30 UTC [Amendment: SEC Form 40-F/A filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/amendment-sec-form-40-fa-filed-by-nervgen-pharma-corp-6749300)
- 2026-10-12 11:15 UTC [NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury](https://www.quantisnow.com/insight/nervgen-announces-first-participant-dosed-in-restore-a-phase-3-6743442)
- 2026-09-25 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6726596)
- 2026-09-25 20:30 UTC [NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments](https://www.quantisnow.com/insight/nervgen-to-restate-previously-filed-financial-statements-recognizing-non-cash-accounting-6726554)
- 2026-09-24 12:27 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6725025)
- 2026-09-09 11:30 UTC [Leadership Update] [NervGen to Host Inaugural R&D Day on September 30, 2026](https://www.quantisnow.com/insight/nervgen-to-host-inaugural-rd-day-on-september-30-2026-6709217)
- 2026-08-13 11:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6679306)
- 2026-08-13 11:30 UTC [Public Offering] [NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/nervgen-reports-second-quarter-2026-financial-results-and-provides-business-6679272)
- 2026-07-13 12:52 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Nervgen Pharma with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-nervgen-pharma-with-a-new-6634951)
- 2026-07-02 21:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6626448)
- 2026-07-02 21:20 UTC [SEC Form SUPPL filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-nervgen-pharma-corp-6626430)
- 2026-06-11 12:10 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Nervgen Pharma](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-nervgen-pharma-6598302)
- 2026-06-01 21:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6582464)
- 2026-05-27 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nervgen-pharma-corp-6573618)
- 2026-05-26 20:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6572648)
- 2026-05-26 20:30 UTC [SEC Form SUPPL filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-nervgen-pharma-corp-6572599)
- 2026-05-26 13:40 UTC [SEC Form F-X] [SEC Form F-X filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-f-x-filed-by-nervgen-pharma-corp-6571650)
- 2026-05-26 13:26 UTC [SEC Form F-10 filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-f-10-filed-by-nervgen-pharma-corp-6571633)
- 2026-05-26 11:15 UTC [NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study](https://www.quantisnow.com/insight/nervgen-announces-positive-independent-blinded-biomechanical-gait-analyses-demonstrating-genuine-6571207)
- 2026-05-22 21:24 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6570540)
- 2026-05-22 21:20 UTC [SEC Form SUPPL filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-nervgen-pharma-corp-6570522)
- 2026-05-22 03:27 UTC [Public Offering] [NervGen Announces Pricing of US$60.0 Million Public Offering of Securities](https://www.quantisnow.com/insight/nervgen-announces-pricing-of-us600-million-public-offering-of-securities-6568668)
- 2026-05-21 20:34 UTC [SEC Form SUPPL filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-suppl-filed-by-nervgen-pharma-corp-6567795)
- 2026-05-21 20:01 UTC [Public Offering] [NervGen Announces Proposed Public Offering of Securities](https://www.quantisnow.com/insight/nervgen-announces-proposed-public-offering-of-securities-6567112)
- 2026-05-18 20:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6560351)
- 2026-05-18 11:15 UTC [Public Offering] [NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/nervgen-reports-first-quarter-2026-financial-results-and-provides-business-6559064)
- 2026-05-15 20:28 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6557786)
- 2026-05-07 20:06 UTC [SEC Form S-8] [SEC Form S-8 filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-nervgen-pharma-corp-6538999)
- 2026-04-27 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6516945)
- 2026-04-27 12:36 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Nervgen Pharma with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-nervgen-pharma-with-a-new-6515763)
- 2026-04-27 11:30 UTC [Leadership Update] [NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer](https://www.quantisnow.com/insight/nervgen-pharma-strengthens-leadership-team-with-appointment-of-keith-vendola-6515466)
- 2026-04-13 11:45 UTC [Conference Announcement] [NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference](https://www.quantisnow.com/insight/nervgen-pharma-to-participate-in-the-hc-wainwright-hcwhome-series-6497177)
- 2026-04-07 11:30 UTC [NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia](https://www.quantisnow.com/insight/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-6490281)
- 2026-03-31 11:45 UTC [NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/nervgen-pharma-reports-full-year-2025-financial-results-and-provides-6477923)
- 2026-03-31 11:30 UTC [SEC Form 40-F filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-40-f-filed-by-nervgen-pharma-corp-6477891)
- 2026-03-13 21:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by NervGen Pharma Corp.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-nervgen-pharma-corp-6447463)
- 2026-03-12 20:15 UTC [NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange](https://www.quantisnow.com/insight/nervgen-pharma-announces-voluntary-delisting-from-tsx-venture-exchange-6444596)
- 2026-03-04 12:30 UTC [Leadership Update] [NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs](https://www.quantisnow.com/insight/nervgen-pharma-appoints-shamim-ruff-as-chief-regulatory-affairs-officer-6428341)
- 2026-02-18 12:30 UTC [NervGen Pharma to Participate at Upcoming Investor Conferences](https://www.quantisnow.com/insight/nervgen-pharma-to-participate-at-upcoming-investor-conferences-6398189)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NGEN
- Earnings history: https://www.quantisnow.com/earnings/NGEN
- Dividend history: https://www.quantisnow.com/dividends/NGEN
- Insider transactions: https://www.quantisnow.com/insiders/NGEN
- Options chain: https://www.quantisnow.com/options/NGEN
- SEC 8-K filings only: https://www.quantisnow.com/company/NGEN/8-k
- RSS and alerts for NGEN: https://www.quantisnow.com/docs/rss-feeds.md